12,13-(pyranosyl)-indolo[2,3-a]pyrrolo[3,4-c]carbazole and 12,13-(pyranosyl)-furo[3,4-c]indolo[2,3-a]carbazoles
    2.
    发明授权
    12,13-(pyranosyl)-indolo[2,3-a]pyrrolo[3,4-c]carbazole and 12,13-(pyranosyl)-furo[3,4-c]indolo[2,3-a]carbazoles 失效
    12,13-(吡喃糖基) - 吲哚并[2,3-a]吡咯并[3,4-c]咔唑和12,13-(吡喃糖基) - 呋喃并[3,4-c]吲哚并[2,3-a] 咔唑

    公开(公告)号:US06569858B2

    公开(公告)日:2003-05-27

    申请号:US10010379

    申请日:2001-11-05

    IPC分类号: C07D49044

    CPC分类号: C07H19/23

    摘要: A compound selected from those of formula (I): wherein: R1 and R2, which may be identical or different, represent a group of formula U-V wherein U represents single bond, or alkylene which is optionally substituted and/or unsaturated, and V is as defined in the description, G represents oxygen, or NR3 wherein R3 is as defined in the description, X represents hydrogen, hydroxy, alkoxy, mercapto or alkylthio, Y represents hydrogen, or X+Y represents carbonyl, X1 represents hydrogen, hydroxy, alkoxy, mercapto or alkylthio, Y1 represents hydrogen, or X1+Y1 represents carbonyl, R4, R5, and R6 are as defined in the description, its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same are useful in the treatment of cancer.

    摘要翻译: 选自式(I)的化合物:其中:R 1和R 2可以相同或不同,表示其中U表示单键的式UV基团,或任选被取代和/或不饱和的亚烷基,V是 G表示氧或NR 3,其中R3如说明书中所定义,X表示氢,羟基,烷氧基,巯基或烷硫基,Y表示氢,或X + Y表示羰基,X1表示氢,羟基, 烷氧基,巯基或烷硫基,Y1表示氢,或X1 + Y1表示羰基,R4,R5和R6如说明书中所定义,其异构体及其药学上可接受的酸或碱加成盐,以及含有它们的药物 可用于治疗癌症。